Cargando…

Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice

In recent years, sarcopenic obesity has been considered central pathological factors in diabetes. This study aimed to compare the effect of luseogliflozin, a sodium-glucose co-transporter-2 inhibitor (SGLT2i), on sarcopenic obesity in comparison to that of a low-carbohydrate diet (LCD). Twenty-week-...

Descripción completa

Detalles Bibliográficos
Autores principales: Hata, Shinnosuke, Okamura, Takuro, Kobayashi, Ayaka, Bamba, Ryo, Miyoshi, Tomoki, Nakajima, Hanako, Kitagawa, Nobuko, Hashimoto, Yoshitaka, Majima, Saori, Senmaru, Takafumi, Okada, Hiroshi, Ushigome, Emi, Nakanishi, Naoko, Takakuwa, Hiroshi, Sasano, Ryoichi, Hamaguchi, Masahide, Fukui, Michiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459736/
https://www.ncbi.nlm.nih.gov/pubmed/36079789
http://dx.doi.org/10.3390/nu14173531
_version_ 1784786583209115648
author Hata, Shinnosuke
Okamura, Takuro
Kobayashi, Ayaka
Bamba, Ryo
Miyoshi, Tomoki
Nakajima, Hanako
Kitagawa, Nobuko
Hashimoto, Yoshitaka
Majima, Saori
Senmaru, Takafumi
Okada, Hiroshi
Ushigome, Emi
Nakanishi, Naoko
Takakuwa, Hiroshi
Sasano, Ryoichi
Hamaguchi, Masahide
Fukui, Michiaki
author_facet Hata, Shinnosuke
Okamura, Takuro
Kobayashi, Ayaka
Bamba, Ryo
Miyoshi, Tomoki
Nakajima, Hanako
Kitagawa, Nobuko
Hashimoto, Yoshitaka
Majima, Saori
Senmaru, Takafumi
Okada, Hiroshi
Ushigome, Emi
Nakanishi, Naoko
Takakuwa, Hiroshi
Sasano, Ryoichi
Hamaguchi, Masahide
Fukui, Michiaki
author_sort Hata, Shinnosuke
collection PubMed
description In recent years, sarcopenic obesity has been considered central pathological factors in diabetes. This study aimed to compare the effect of luseogliflozin, a sodium-glucose co-transporter-2 inhibitor (SGLT2i), on sarcopenic obesity in comparison to that of a low-carbohydrate diet (LCD). Twenty-week-old male db/db mice were fed a normal diet (Ctrl), LCD, and normal diet with 0.01% w/w luseogliflozin (SGLT2i) for eight weeks. Skeletal muscle mass and grip strength decreased in the LCD group mice compared to those in the control group, while they increased in the SGLT2i group mice. The amino acid content in the liver, skeletal muscle, and serum were lower in the LCD group than those in the Ctrl group but increased in the SGLT2i group mice. Short-chain fatty acids in rectal feces were lower in the LCD group mice than those in the Ctrl group, whereas they were higher in the SGLT2i group mice. The abundance of Gammaproteobacteria, Enterobacteriaceae, Escherichia, Enterobacterales, and Bacteroides caccae species increased in the LCD group compared to the other two groups, whereas the abundance of Syntrophothermus lipocalidus, Syntrophomonadaceae family, Parabacteroidesdistasonis distasonis, and the genus Anaerotignum increased in the SGLT2i group. Luseogliflozin could prevent sarcopenic obesity by improving amino acid metabolism.
format Online
Article
Text
id pubmed-9459736
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94597362022-09-10 Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice Hata, Shinnosuke Okamura, Takuro Kobayashi, Ayaka Bamba, Ryo Miyoshi, Tomoki Nakajima, Hanako Kitagawa, Nobuko Hashimoto, Yoshitaka Majima, Saori Senmaru, Takafumi Okada, Hiroshi Ushigome, Emi Nakanishi, Naoko Takakuwa, Hiroshi Sasano, Ryoichi Hamaguchi, Masahide Fukui, Michiaki Nutrients Article In recent years, sarcopenic obesity has been considered central pathological factors in diabetes. This study aimed to compare the effect of luseogliflozin, a sodium-glucose co-transporter-2 inhibitor (SGLT2i), on sarcopenic obesity in comparison to that of a low-carbohydrate diet (LCD). Twenty-week-old male db/db mice were fed a normal diet (Ctrl), LCD, and normal diet with 0.01% w/w luseogliflozin (SGLT2i) for eight weeks. Skeletal muscle mass and grip strength decreased in the LCD group mice compared to those in the control group, while they increased in the SGLT2i group mice. The amino acid content in the liver, skeletal muscle, and serum were lower in the LCD group than those in the Ctrl group but increased in the SGLT2i group mice. Short-chain fatty acids in rectal feces were lower in the LCD group mice than those in the Ctrl group, whereas they were higher in the SGLT2i group mice. The abundance of Gammaproteobacteria, Enterobacteriaceae, Escherichia, Enterobacterales, and Bacteroides caccae species increased in the LCD group compared to the other two groups, whereas the abundance of Syntrophothermus lipocalidus, Syntrophomonadaceae family, Parabacteroidesdistasonis distasonis, and the genus Anaerotignum increased in the SGLT2i group. Luseogliflozin could prevent sarcopenic obesity by improving amino acid metabolism. MDPI 2022-08-27 /pmc/articles/PMC9459736/ /pubmed/36079789 http://dx.doi.org/10.3390/nu14173531 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hata, Shinnosuke
Okamura, Takuro
Kobayashi, Ayaka
Bamba, Ryo
Miyoshi, Tomoki
Nakajima, Hanako
Kitagawa, Nobuko
Hashimoto, Yoshitaka
Majima, Saori
Senmaru, Takafumi
Okada, Hiroshi
Ushigome, Emi
Nakanishi, Naoko
Takakuwa, Hiroshi
Sasano, Ryoichi
Hamaguchi, Masahide
Fukui, Michiaki
Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice
title Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice
title_full Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice
title_fullStr Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice
title_full_unstemmed Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice
title_short Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice
title_sort gut microbiota changes by an sglt2 inhibitor, luseogliflozin, alters metabolites compared with those in a low carbohydrate diet in db/db mice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459736/
https://www.ncbi.nlm.nih.gov/pubmed/36079789
http://dx.doi.org/10.3390/nu14173531
work_keys_str_mv AT hatashinnosuke gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice
AT okamuratakuro gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice
AT kobayashiayaka gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice
AT bambaryo gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice
AT miyoshitomoki gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice
AT nakajimahanako gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice
AT kitagawanobuko gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice
AT hashimotoyoshitaka gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice
AT majimasaori gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice
AT senmarutakafumi gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice
AT okadahiroshi gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice
AT ushigomeemi gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice
AT nakanishinaoko gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice
AT takakuwahiroshi gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice
AT sasanoryoichi gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice
AT hamaguchimasahide gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice
AT fukuimichiaki gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice